Thermo Fisher Scientific's new specialty diagnostics technologies to help clinicians improve patient care

Thermo Fisher Scientific Inc. today highlighted its comprehensive range of specialty diagnostics products at the annual conference of the American Association for Clinical Chemistry (AACC).

A number of new products are being showcased at Thermo Scientific booth 2215 during the Clinical Lab Expo at the AACC conference, being held at the Los Angeles Convention Center from July 17-19.

“Healthcare professionals increasingly rely on new diagnostic tools to provide the information they need to make critical decisions involving patient care,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “Our growing offering of specialty diagnostics enables physicians to make faster, more accurate diagnoses with the goal of improving patient outcomes.”

Solutions to Improve Productivity in the Clinical Laboratory

Thermo Fisher announced that its new Thermo Scientific QMS™ Tacrolimus immunoassay has been CE marked for sale in the European Union. The liquid, ready-to-use immunoassay provides bar-coded reagents to run on the Thermo Scientific Indiko bench-top chemistry analyzer. The product is not yet available for sale in the United States.
The company also introduced a new generation of its Indiko platform, the Thermo Scientific Indiko Plus analyzer. Featuring the same compact design as its predecessor, the Indiko Plus analyzer is designed to deliver higher throughput for routine clinical research applications, including drugs-of-abuse testing and therapeutic drug monitoring.

In addition, Thermo Fisher introduced immunoassay and chemistry controls that improve the clinical laboratory workflow by concentrating the number of analytes in a single vial. The new Thermo Scientific MAS Omni·CORE control consolidates general chemistry and serum protein quality control (QC) processing into a single solution that offers different levels of testing to streamline the workflow and reduce cost. The company’s new Thermo Scientific MAS Omni·Immune immunoassay control consolidates routine immunoassay, tumor marker and specialty immunoassay QC processing.

Leading Portfolio of Immunodiagnostics for Improved Patient Care

Thermo Fisher continues to expand its extensive capabilities in the clinical diagnosis and monitoring of allergies, asthma and autoimmune diseases by introducing several new assays at AACC. The Thermo Scientific EliA Rheumatoid Factor Assays, cleared by the FDA in Nov. 2011, provides clinicians with a reliable and simple tool to aid in the early diagnosis of rheumatoid arthritis. In addition, Thermo Scientific ImmunoCAP Tryptase Assay, cleared by the FDA in Feb. 2012, measures levels of a specific enzyme in serum or plasma to provides an earlier indication of systemic mastocytosis, a rare blood disorder.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. has approximately 39,000 employees and serves customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries.